Last reviewed · How we verify
KC1036
KC1036 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.
At a glance
| Generic name | KC1036 |
|---|---|
| Sponsor | Beijing Konruns Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of KC1036 has not been publicly disclosed in detail, it is being developed by Beijing Konruns Pharmaceutical as an oncology therapeutic in Phase 3 clinical trials. The drug likely functions by inhibiting aberrant signaling pathways that drive tumor growth, though the specific kinase target and mechanism require further public disclosure.
Approved indications
Common side effects
Key clinical trials
- KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer (PHASE2)
- A Study of KC1036 in Patients with Advanced Thymic Tumors (PHASE2)
- To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors (PHASE1, PHASE2)
- A Study of KC1036 in Patients with Advanced Solid Tumors (PHASE1)
- A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma (PHASE2)
- A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer (PHASE3)
- A Food Effect Study of KC1036 in Healthy Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KC1036 CI brief — competitive landscape report
- KC1036 updates RSS · CI watch RSS
- Beijing Konruns Pharmaceutical Co., Ltd. portfolio CI